This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
by Zacks Equity Research
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
AGENNegative Net Change VRNAPositive Net Change APLSNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
by Ahan Chakraborty
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
EXELPositive Net Change ALKSNegative Net Change VRNAPositive Net Change KNSAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
by Sundeep Ganoria
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
SNYNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs gene-editing gene-therapy medical messenger-rna pharmaceuticals
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
VRTXNegative Net Change EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change
biotechs
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
by Zacks Equity Research
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
EXELPositive Net Change PBYINegative Net Change RCKTNegative Net Change SPRONegative Net Change
biotechs
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
by Zacks Equity Research
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
BIIBNegative Net Change AGENNegative Net Change VRNAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
by Zacks Equity Research
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
GSKNegative Net Change NVSNegative Net Change QGENNegative Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock Gains on Encouraging Flu Vaccine Data
by Zacks Equity Research
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
GSKNegative Net Change MRNANegative Net Change AGENNegative Net Change AMRNPositive Net Change
biotechs medical messenger-rna vaccines
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
BAYRYNegative Net Change AGENNegative Net Change RARENegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
by Zacks Equity Research
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change VORNegative Net Change
biotechs
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for ADMA Biologics Stock Options
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
ADMANo Net Change
biotechnology biotechs medical
Will Strong Asceniv Sales Drive ADMA Biologics Further?
by Ekta Bagri
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
GRFSNegative Net Change ADMANo Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
by Zacks Equity Research
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
by Ahan Chakraborty
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
by Zacks Equity Research
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
SNYNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
by Zacks Equity Research
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
BAYRYNegative Net Change AGENNegative Net Change KRYSNegative Net Change IMCRNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
by Zacks Equity Research
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
BAYRYNegative Net Change AGENNegative Net Change AMRNPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
REGNNegative Net Change VRTXNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
by Zacks Equity Research
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
SNYNegative Net Change AGENNegative Net Change AMRNPositive Net Change IMCRNegative Net Change
biotechs medical pharmaceuticals
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
ADMANo Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
GSKNegative Net Change GILDNegative Net Change EXELPositive Net Change MIRMNegative Net Change
biotechs